Bayer’s small molecule PRMT5 inhibitor has been approved for clinical trials in China
August 29, 2025
Source: drugdu
100
The official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (CFDA) announced that Bayer has received implicit approval for clinical trials for its Category 1 new drug, BAY 3713372 tablets, intended for the treatment of methylthioadenosine phosphorylase-deficient (MTAP-DEL) solid tumors. This is an oral small molecule PRMT5 inhibitor. In March of this year, Bayer and Puhe Pharmaceuticals announced a global licensing agreement, granting them exclusive global rights to develop, manufacture, and commercialize this product.
Comment: Bayer's small molecule PRMT5 inhibitor has received clinical approval in China, which is expected to bring new hope to patients with MTAP-DEL solid tumors.It selectively targets cancer cells, has high safety, and has received technical support through cooperation with Puhe Pharmaceutical. Subsequent clinical data is highly anticipated.
https://finance.eastmoney.com/a/202508273495486977.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
